Mostrar el registro sencillo del ítem

dc.contributor.authorAcebedo Martínez, Francisco Javier
dc.contributor.authorAlarcón-Payer, Carolina
dc.contributor.authorRodríguez Domingo, Lucía
dc.contributor.authorDomínguez Martín, Alicia 
dc.contributor.authorGómez Morales, Jaime
dc.contributor.authorChoquesillo Lazarte, Duane
dc.date.accessioned2021-11-05T08:04:37Z
dc.date.available2021-11-05T08:04:37Z
dc.date.issued2021
dc.identifier.citationAcebedo-Martínez, F.J.; Alarcón-Payer, C.; RodríguezDomingo, L.; Domínguez-Martín, A.; Gómez-Morales, J.; ChoquesilloLazarte, D. Furosemide/NonSteroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation. Crystals 2021, 11, 1339. https://doi.org/10.3390/ cryst11111339es_ES
dc.identifier.urihttp://hdl.handle.net/10481/71298
dc.description.abstractThe design of drug–drug multicomponent pharmaceutical solids is one the latest drug development approaches in the pharmaceutical industry. Its purpose is to modulate the physicochemical properties of active pharmaceutical ingredients (APIs), most of them already existing in the market, achieving improved bioavailability properties, especially on oral administration drugs. In this work, our efforts are focused on the mechanochemical synthesis and thorough solid-state characterization of two drug–drug cocrystals involving furosemide and two different non-steroidal anti-inflammatory drugs (NSAIDs) commonly prescribed together: ethenzamide and piroxicam. Besides powder and single crystal X-ray diffraction, infrared spectroscopy and thermal analysis, stability, and solubility tests were performed on the new solid materials. The aim of this work was evaluating the physicochemical properties of such APIs in the new formulation, which revealed a solubility improvement regarding the NSAIDs but not in furosemide. Further studies need to be carried out to evaluate the drug–drug interaction in the novel multicomponent solids, looking for potential novel therapeutic alternatives.es_ES
dc.description.sponsorshipy Spanish Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (MICIU) and co-funded with FEDER, UE, Project No. PGC2018- 102047-B-I00 (MCIU/AEI/FEDER, UE) and Project No. B-FQM-478-UGR20 (FEDER-Universidad de Granada, Spain).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectDrug–drug cocrystales_ES
dc.subjectFurosemidees_ES
dc.subjectEthenzamidees_ES
dc.subjectPiroxicames_ES
dc.subjectMechanochemical synthesises_ES
dc.titleFurosemide/Non-Steroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/cryst11111339


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España